Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Fatigue, Influenza like illness, Joint stiffness, Overdose
Clinical narrative: weak; tired; a little joint stiffness; Slight rash developed on the stomach area.; typical soreness; flu like symptoms; he has drawn more than the required volume (0.5mL instead of 0.3mL).; This is a spontaneous report from a contactable pharmacist. This Pharmacist reported similar events for 3 patients. This report is for 2nd of 3 patients.  A 61-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: EL3302; Expiration Date: 28May2021), dose 2 via an unspecified route of administration on 26Feb2021 (at the age of 61-years-old) as dose 2, 0.5ml single for covid-19 immunisation. The patient medical history was unknown. Patient had no illness at the time of vaccination and no fever. There were no concomitant medications. Historical Vaccine included BNT162B2 (Batch/Lot number: EL3302 exp 28Mar2021) as dose 1 on 05Feb2021 for Covid-19 immunisation (at the age of 61-year-old). The patient experienced "he has drawn more than the required volume (0.5ml instead of 0.3ml)" (overdose) on 26Feb2021 and on an unspecified date weak, tired, a little joint stiffness, slight rash developed on the stomach area, typical soreness and flu like symptoms. The reporter was seeking guidance as he had overdosed the patient. No patient identifiers were provided but the reporter has firsthand knowledge of the patient and was reporting on a specific patient. It was reported the patient experienced just weak and tired, and mentioned a little joint stiffness that lasted a couple days. Slight rash developed on the stomach area.  Prior Vaccination(within 4 weeks) was none. Properly diluted vial so only slight overdose, not full vial overdose. Pharmacist monitored patient for a week and she has been fine after her symptoms resolved. She had the expected typical soreness and flu like symptoms for 24-48 hours. Pharmacist provided preferred address to mail follow up letter to, and corrected spelling of last name. Outcome of the events were recovered.   Follow-up (08Mar2021): This is a follow-up spontaneous report from a Pfizer-sponsored program COVAX US Support. A contactable pharmacist reported for a patient included dose of the drug admistered by mistake.   Follow-up (08Mar2021): This is a follow-up spontaneous report from a contactable Pharmacist. This Pharmacist reported in response to HCP letter sent via telephonic follow up which included no relevant information for the patient. Pharmacist confirmed he would pass along the questionnaires to primary reporter once in office.  Follow-up (11Mar2021): This is a follow-up spontaneous report from a contactable Pharmacist. This Pharmacist reported in response to HCP letter sent via telephonic follow up which included information about dose 1 and dose along with date and lot/batch number and outcome of the event.   Follow-up (08Mar2021): This follow up report contains no new safety information.  Follow-up (11Mar2021): This is a follow-up spontaneous report from a contactable pharmacist. This pharmacist reported for a patient included about the safety of the patient which said the patient was okay that day.  Follow-up (11Mar2021): This is a follow-up spontaneous report from a contactable Pharmacist. This Pharmacist reported in response to HCP letter sent via telephonic follow up which included duplicate information about both the dose.   No follow-up attempts are possible. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021216069 Same reporter/drug/event, different patient.;US-PFIZER INC-2021223836 Same reporter/drug/event, different patient.